Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12507067 | 0.87 | MEN1 (0.44) | KMT2AMEN1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL14077055 | 0.86 | MEN1 (0.43) | KMT2AMEN1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL2184331 | 0.84 | MEN1 (0.54) | KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL3996377 | 0.80 | MEN1 (0.50) | KMT2AMEN1SMN1; SMN2CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL28440326 | 0.79 | MEN1 (0.53) | KMT2AMEN1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL2183729 | 0.79 | KMT2A (0.74) | KMT2AMEN1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL2183769 | 0.78 | SMPD1 (0.35) | KMT2AMEN1SMN1; SMN2L3MBTL1SMPD1 | |
| SCHEMBL12506969 | 0.72 | HRH3 (0.47) | RAB9AMAPT | |
| Hydrochloric Acid SCHEMBL28450778 | 0.71 | MEN1 (0.44) | KMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL2184070 | 0.71 | HRH3 (0.46) | RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064194-B1 | N-HYDROXYAMIDINOHETEROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE HOLDINGS CORP (US) | 2018-11-07 | — | — | EP | disclosed |
| US-8507541-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507541-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2013-08-13 | — | — | US | disclosed |
| US-20110165188-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Incyte Corporation a Delaware corporation | 2011-07-07 | — | — | US | disclosed |
| US-20110165188-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Incyte Corporation a Delaware corporation | 2011-07-07 | — | — | US | disclosed |
| EP-2064194-A2 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Incyte Corporation (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080214546-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214546-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214546-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2008036653-A2 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008036653-A2 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214546-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, HNMT | KMT2A 675/4885MEN1 2391/4885SMN1; SMN2 3241/4885 |
| US-20110165188-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, HNMT | KMT2A 675/4885MEN1 2391/4885SMN1; SMN2 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.